Rapid Assessment of Sentinel Lymph Node Metastasis Status Using a Pan-CK-targeting NIR-II Fluorescent Probe in Breast Cancer

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

Breast malignant tumors are a serious threat to women's health, and the current treatment for breast malignant tumors is still dominated by surgery, but the problems faced by patients after surgery such as edema and tumor recurrence are still relatively common, and the high recurrence rate and the occurrence of postoperative complications are closely related to the removal of metastatic lymph nodes during surgery. Therefore, accurate assessment of sentinel lymph node (SLN) metastases is essential to determine the extent of axillary lymph node dissection (ALND) and minimize complications. In this study, we developed a new technique that can rapidly distinguish between metastatic lymph nodes and normal sentinel lymph nodes (SLNs) in breast cancer patients. Briefly, fresh tissue is incubated with the probe and imaged immediately after intraoperative sentinel lymph node resection to identify the metastatic status of SLN. The accuracy of fluorescence imaging is confirmed by pathological diagnosis.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• Adult patients between 18-75 years of age

• Patients presenting with a breast nodule or mass presumed to be resectable on pre-operative assessment

• Breast cancer patients who are scheduled to undergo sentinel lymph node biopsy or axillary lymph node dissection;

• Good operative candidate

• Subject capable of giving informed consent and participating in the process of consent

Locations
Other Locations
China
Yunnan Cancer Hospital, Kunming, Yunnan 650118
RECRUITING
Kunming
Contact Information
Primary
Junhong Chen, Postgraduate
1145644908@qq.com
86+17782287838
Backup
Weiling Chen, Doctor
913208146@qq.com
86+13646039812
Time Frame
Start Date: 2025-02-01
Estimated Completion Date: 2026-12-01
Participants
Target number of participants: 60
Treatments
NIR-II probe incubation
NIR-II probe incubation Group/Cohort Description: Freshly excised SLNs will be fully immersed in NIR-II probe ((i.e:ICG-CK) incubation solution (6.25, 12.5, 25, 50, 100 ug/mL) for 1, 3, 5, 7, or 10 min, then rinsed with PBST buffer for 5 min and dried with absorbent paper. NIR-II fluorescence imaging will then be performed under the DPM NIR-II system. The correlation between pathological features and fluorescence information will be further analyzed.
Related Therapeutic Areas
Sponsors
Collaborators: Xiang'an Hospital of Xiamen University
Leads: Yunnan Cancer Hospital

This content was sourced from clinicaltrials.gov